SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of the earliest event reported): November 1, 2004
NEUROCRINE BIOSCIENCES, INC.
(Exact name of registrant as specified in its charter)
| | | | | |
| Delaware | | 0-28150 | | 33-0525145 |
(State or other
jurisdiction of
incorporation or
organization) | | (Commission File
Number) | | (IRS Employer Identification No.) |
| | | | | |
12790 El Camino Real, San Diego, CA
| | 92130 |
(Address of principal executive offices)
| | (Zip Code) |
Registrant’s telephone number, including area code:(858) 617-7600
N/A
(Former name or former address, if changed since last report.)
TABLE OF CONTENTS
ITEM 2.02 RESULTS OF OPERATION AND FINANCIAL CONDITION.
On November 1, 2004, Neurocrine Biosciences, Inc. announced its financial results for the quarter ended September 30, 2004. The full text of the press release issued in connection with the announcement is filed as Exhibit 99.1 to this Current Report on Form 8-K.
In accordance with General Instruction B.2. of Form 8-K, the information in this Current Report of Form 8-K, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, (“Exchange Act”) or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS.
(c) EXHIBITS. The following exhibits are filed herewith:
| | | |
| Exhibit | | |
Number
| | Description of Exhibit
|
| 99.1 | | Press Release dated November 1, 2004 |
1
SIGNATURES
Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
| | | | | |
| Dated: November 1, 2004 | NEUROCRINE BIOSCIENCES, INC.
| |
| | /s/ PAUL W. HAWRAN | |
| | Paul W. Hawran | |
| | Executive Vice President
and Chief Financial Officer | |
| |
2
